The forecast, shared by the pharmaceutical distributor to investors at a conference, comes despite reports of slowing volume.
The stock was also helped by a report from Lazard Capital Markets with data showing pharmaceutical sales rose in August, up 1.9 percent, more than double what was reported for the entire second quarter, according to reports.
McKesson closed up 3.24 points to 62.98.
Read the WSJ report about McKesson.
